Floatz logo

CABAZITAXEL

Metastatic Castration Resistant Prostate Cancer

Jeffrey Yachnin M.D., PhD.Small moleculePhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
89/ 100

Competitive context

17 Active assets in the Metastatic Castration Resistant Prostate Cancer cohort.

Asset / SponsorPhaseRating
Enzalutamide
Jiangsu HengRui Medicine Co., Ltd.
Phase 4BBB
Abiraterone Acetate
Jiangsu HengRui Medicine Co., Ltd.
Phase 3BBB
PREDNISONE TABLETS
Jiangsu HengRui Medicine Co., Ltd.
Phase 3BB
177lu-psma
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2BB
Docetaxel
National Cancer Institute (NCI)
Phase 3BB

View all 39 →

Same molecule, other indications

CABAZITAXEL is also rated in:

metastatic prostate carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
prostate cancerDormant
BB
Indicative ·
66 / 100
View asset →
prostate adenocarcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →